Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Journal of Inherited Metabolic Disease|October 9, 2024
Extended long-term efficacy and safety of velmanase alfa treatment up to 12 years in patients with alpha-mannosidosisNathalie Guffon, Line Borgwardt, Anna Tylki-Szymańska, et al.
American Journal of Nephrology|June 10, 2021
Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ DamagePeter Kolkhof, Elke Hartmann, Alexius Freyberger, et al.
Clinical Pharmacokinetics|November 17, 2021
Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion CriteriaSebastiaan Camiel Goulooze, Nelleke Snelder, Andreas Seelmann, et al.
Clinical Pharmacokinetics|November 13, 2021
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event AnalysisPaul van den Berg, Martijn Ruppert, Emir Mesic, et al.
American Journal of Nephrology|October 31, 2019
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease TrialLuis M Ruilope, Rajiv Agarwal, Stefan D Anker, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 6, 2020
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenoneRajiv Agarwal, Stefan D Anker, George Bakris, et al.
The New England Journal of Medicine|August 27, 2021
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 DiabetesBertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, et al.
Pageof 4